CWP
AXDX

Concord Wealth Partners’s Accelerate Diagnostics AXDX Stock Holding History

Concord Wealth Partners’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-29
Closed -$2K – 1299
2021
Q3 		$2K Buy
+29
New +$1.89K ﹤0.01% 732

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Concord Wealth Partners's AXDX Position: Q4 2021 in Review

Concord Wealth Partners sold out of Accelerate Diagnostics (AXDX) in Q4 2021, closing a stake of 29 shares — an estimated $2K sold.

Concord Wealth Partners first reported a position in AXDX in Q3 2021 and held it in 1 quarter. The position peaked at $2K in Q3 2021. 107 funds tracked by Wall St. Rank hold AXDX as of Q4 2021.

  • Concord Wealth Partners reported no remaining Accelerate Diagnostics position as of Q4 2021 after selling out during the quarter.
  • Concord Wealth Partners sold 29 Accelerate Diagnostics shares in Q4 2021, an estimated $2K.
  • Concord Wealth Partners first reported a position in Accelerate Diagnostics in Q3 2021 and held it in 1 quarter.
  • Concord Wealth Partners's Accelerate Diagnostics position peaked at $2K in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2021.

Based on Concord Wealth Partners's 13F filing for Q4 2021, filed 21 Jan 2022.